Opexa Therapeutics Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Opexa Therapeutics is a biotechnology company focused on developing personalized immunotherapies for autoimmune diseases, including multiple sclerosis and neuromyelitis optica. Its approach relies on a proprietary T-cell technology to tailor treatments to individual patients, aiming to influence disease processes with greater precision. The lead product candidate, Tcelna, was in a Phase IIb program (the Abili-T trial) for Secondary Progressive Multiple Sclerosis, with top-line results expected in the fourth quarter of 2016. The company describes its mission as advancing Precision Immunotherapy to align the interests of patients, employees and shareholders.

Based in The Woodlands, Texas, Opexa Therapeutics operates in the biotechnology research sector and maintains a relatively small workforce. It has pursued corporate development activity, including a merger with Acer America Corporation in 2021.

Sign up for free to view info

Company overview Employee directory